Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.

Abstract

Allogeneic hematopoietic cell transplantation is a curative procedure for hematologic malignancies but is associated with a significant risk of non-relapse mortality (NRM). The Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) is a prognostic tool that discriminates this risk in all age groups. A recent survey of transplant physicians demonstrated that 79% of pediatric providers used the HCT-CI infrequently, and most reported concerns about its applicability in the younger population. We conducted a retrospective study using the Center for International Blood and Marrow Transplant Research database to examine the impact of expanded HCT-CI definitions on NRM in pediatric and young adult patients with hematologic malignancies. We included 5790 patients <40 years old receiving allogeneic transplants between 2008 and 2017 to examine broader definitions of comorbidities in the HCT-CI, including history of mechanical ventilation and fungal infection, estimated glomerular filtration rate, and body mass index (BMI) percentiles. Multivariable Fine-Gray models were created to determine the effect of each HCT-CI defining comorbidity and its modification on NRM and were used to develop 2 novel risk scores. We next developed the expanded HCT-CI for children and young adults (youth with malignancies; expanded ymHCT-CI), where 23% patients had an increased comorbidity score, compared to the HCT-CI. Comorbidities with hazard ratio < 1.2 were then removed to create the simplified HCT-CI for children and young adults (youth with malignancies; simplified ymHCT-CI), which demonstrated higher scores corresponded to a greater risk of NRM (P < .001). These novel comorbidity indexes with broader definitions are more relevant to pediatric and young adult patients, and prospective studies are needed to validate these in the younger patient population. It remains to be seen whether the development of these pediatric-specific and practical risk indexes increases their use by the pediatric transplant community.

• Authors: Brian D Friend, Larisa Broglie, Brent R Logan, Saurabh Chhabra, Caitrin Bupp, Gary Schiller, Amer Beitinjaneh, Miguel Angel Diaz Perez, Gregory M T Guilcher, Hasan Hashem, Gerhard C Hildebrandt, Maxwell M Krem, Hillard M Lazarus, Taiga Nishihori, Roomi Nusrat, Seth J Rotz, Baldeep Wirk, Matthew Wieduwilt, Marcelo Pasquini, Bipin N Savani, Edward A Stadtmauer, Mohamed L Sorror, Monica S Thakar
• Journal: Transplantation and cellular therapy (Transplant Cell Ther) Vol. 29 Issue 2 Pg. 123.e1-123.e10 (02 2023) ISSN: 2666-6367 [Electronic] United States
• PMID: 36442769 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.)
• Copyright: Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Topics

• Humans
• Adolescent
• Young Adult
• Child
• Adult
• Retrospective Studies
• Transplantation, Homologous
• Neoplasm Recurrence, Local
• Hematopoietic Stem Cell Transplantation (methods)
• Hematologic Neoplasms (therapy, epidemiology)